Walder Wyss advises Alentis on its USD 105m Series C funding
Walder Wyss advises Swiss biotech Alentis Therapeutics in connection with their USD 105m Series C funding to support the development of its lead assets. The funding round was led by Jeito Capital together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital.
Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. The financing will support Phase II and Phase I programs of Alentis’ lead investigational products ALE.F02 and ALE.C04 respectively as well as the CLDN1 platform development.
The Walder Wyss team includes partner Alexander Gutmans (pictured), associates Karina Tschon and Lucas Maurer (all corporate/m&a and venture capital) as well as Manuel Bigler (managing associate, IP/Licensing) and Katja Schott-Morgenroth (partner, notarial services).
